Varizig approved to reduce chickenpox symptoms
(HealthDay)—Varizig (varicella zoster immune globulin) has been approved by the U.S. Food and Drug Administration to minimize chickenpox symptoms when administered within four days of exposure to the virus ...
Medications
Dec 22, 2012 |
not rated yet |
0
Gattex approved for short bowel syndrome
(HealthDay)—Gattex (teduglutide) has been approved by the U.S. Food and Drug Administration to treat nutritional problems caused by short bowel syndrome.
Medications
Dec 22, 2012 |
1 / 5 (1) |
1
High court asked to block morning-after pill rule
(AP)—Hobby Lobby Stores is asking the U.S. Supreme Court to block part of the federal health care law that requires it to provide insurance coverage for the morning-after pill and similar emergency contraception pills.
Medications
Dec 21, 2012 |
not rated yet |
1
FDA panel recommends against 1st drug for chronic fatigue syndrome
(HealthDay)—A U.S. Food and Drug Administration advisory committee on Thursday recommended against approval of the first proposed drug to treat chronic fatigue syndrome.
Medications
Dec 21, 2012 |
1 / 5 (1) |
1
|
Big Pharma cashes in on HGH abuse
An Associated Press investigation shows that a federal crackdown on illicit foreign supplies of human growth hormone has failed to stop rampant misuse, and instead has driven record sales of the drug by some of the world's ...
Medications
Dec 21, 2012 |
not rated yet |
0
FDA panel considers 1st drug for chronic fatigue syndrome
(HealthDay)—A U.S. Food and Drug Administration advisory committee will meet Thursday to consider approval of the first drug to treat chronic fatigue syndrome.
Medications
Dec 20, 2012 |
4.5 / 5 (2) |
0
|
Merck says cholesterol drug failed to show benefit
Drugmaker Merck & Co. said it will not seek U.S. approval for its cholesterol drug Tredaptive and is recommending doctors abroad stop prescribing it to new patients, based on failed study results.
Medications
Dec 20, 2012 |
not rated yet |
0
First human tests of meth medication completed
(Medical Xpress)—InterveXion Therapeutics LLC and the University of Arkansas for Medical Sciences (UAMS) have successfully completed dosing in the first human safety study of a medication to help methamphetamine users fight ...
Medications
Dec 20, 2012 |
not rated yet |
0
|
The drugs don't work
(Medical Xpress)—Drugs that do not represent value for money or are medically unproven may be increasingly reaching one of Europe's largest pharmaceutical markets, according to research undertaken by Cambridge ...
Medications
Dec 20, 2012 |
4 / 5 (4) |
0
|
Innovative method to deliver THC: Transmucosal patch increases drug's absorption
(Medical Xpress)—An innovative delivery method for tetrahydrocannabinol, the main psychoactive constituent of Cannabis, is being developed at the University of Mississippi.
Medications
Dec 20, 2012 |
not rated yet |
0
Germany's Merck suffers setback with cancer drug
German pharmaceutical company Merck KgaA says a late stage trial of a new lung cancer drug has failed to meet expectations.
Medications
Dec 19, 2012 |
not rated yet |
0
Sleeping pills owe half their benefits to placebo effect, study finds
Half of the benefit of taking sleeping pills comes from the placebo effect, according to a major new study published in the British Medical Journal.
Medications
Dec 18, 2012 |
5 / 5 (3) |
0
|
Regular aspirin use ten or more years ago associated with increased risk of type of age-related macular degeneration
Among nearly 5,000 study participants, regular aspirin use reported ten years prior was associated with a small but statistically significant increase in the risk of neovascular age‑related macular degeneration, according ...
Medications
Dec 18, 2012 |
5 / 5 (1) |
0
|
Amgen to pay record $762 mn fine over anemia drug (Update)
US pharmaceutical giant Amgen has pleaded guilty to illegally introducing a mislabeled drug for treating anemia onto the market and will pay a record $762 million fine, officials said Wednesday.
Medications
Dec 18, 2012 |
5 / 5 (1) |
0
Researchers find model system to study promising cancer drug
Researchers have found that the budding yeast (Saccharomyces cerevisiae) is an acceptable model system to study KP1019, an anti-cancer drug that uses ruthenium, a rare metal, a new study found. Researchers had previously been i ...
Medications
Dec 18, 2012 |
5 / 5 (1) |
0
